BridgeBio Pharma BBIO Deconsolidation Gain (Loss), Amount, Including Adjustments
Deconsolidation Gain (Loss), Amount, Including Adjustments at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept bbio:DeconsolidationGainLossAmountIncludingAdjustments.
The official record: BridgeBio Pharma’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's deconsolidation gain (loss), amount, including adjustments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's deconsolidation gain (loss), amount, including adjustments?
- BridgeBio Pharma (BBIO) reported deconsolidation gain (loss), amount, including adjustments of $0 in Q4 2025.
- How has BridgeBio Pharma's deconsolidation gain (loss), amount, including adjustments changed year-over-year?
- BridgeBio Pharma's deconsolidation gain (loss), amount, including adjustments decreased by 100.0% year-over-year, from $44.58M to $0.
- What is the long-term trend for BridgeBio Pharma's deconsolidation gain (loss), amount, including adjustments?
- Over 2 years (2023 to 2025), BridgeBio Pharma's deconsolidation gain (loss), amount, including adjustments has grown at a -100.0% compound annual growth rate (CAGR), from -$1.24M to $0.
- What does deconsolidation gain (loss), amount, including adjustments mean?
- This represents the gain or loss recognized when the company loses control of a subsidiary or investment, requiring it to be deconsolidated from the financial statements. It is a non-cash accounting adjustment reflecting the fair value of the remaining interest versus the carrying value.